Company Analysis
Sign in

Viridian Therapeutics, Inc. (VRDN)

Nasdaq: VRDN · Pharmaceutical Preparations · Waltham, MA · filing with the SEC since 2013
Full chart Alerts Compare
Grade5.8
◀ Past 4.6● Present 5.1▶ Future 7.1
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

24 patents granted to the 6 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Viridian Therapeutics, Inc.’s names, not what it holds today.

Patents granted
24
24 utility, 1976 to Dec 31, 2025
Granted in 2025
2
Against none in 2024 and 1 in 2023
Applications published
54
5 of them in 2025
Names they are printed under
6
a former name, its own name
By yearGrantedApplications published
'12'13'14'15'16'17'18'19'20'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals3
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name6 counted
MIRAGEN THERAPEUTICS, INC. a former name
US, as the owner printed on each patent
20 granted
11 published
MIRAGEN THERAPEUTICS, INC. a former name
named as the applicant on its applications, in US
0 granted
25 published
Viridian Therapeutics, Inc. its own name
named as the applicant on its applications, in US
0 granted
14 published
Viridian Therapeutics, Inc. its own name
US, as the owner printed on each patent
3 granted
3 published
Signal Genetics LLC a former name
named as the applicant on its applications, in US
0 granted
1 published
Signal Genetics, Inc. a former name
US, as the owner printed on each patent
1 granted
0 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Sep 2, 202512,404,337Compositions, doses, and methods for treatment of thyroid eye diseasePharmaceuticalsViridian Therapeutics, Inc.
Sep 2, 202512,404,335Compositions and methods for treatment of thyroid eye diseasePharmaceuticalsViridian Therapeutics, Inc.
Jan 10, 202311,548,951Compositions and methods for treatment of thyroid eye diseasePharmaceuticalsViridian Therapeutics, Inc.
Jul 2, 201910,337,005Oligonucleotide-based inhibitors comprising locked nucleic acid motifPharmaceuticalsMIRAGEN THERAPEUTICS, INC.
Jun 11, 201910,316,318Oligonucleotide compositions and uses thereofPharmaceuticalsMIRAGEN THERAPEUTICS, INC.
May 7, 201910,280,422MiR-92 inhibitors and uses thereofPharmaceuticalsMIRAGEN THERAPEUTICS, INC.
Dec 4, 201810,144,930Inhibitors of MYH7B and uses thereofPharmaceuticalsMIRAGEN THERAPEUTICS, INC.
Jul 24, 201810,030,042Synthesis of bicyclic nucleosidesOrganic fine chemistryMIRAGEN THERAPEUTICS, INC.
Jul 3, 201810,011,833Bridged bicyclic nucleosidesPharmaceuticalsMIRAGEN THERAPEUTICS, INC.
Jun 12, 20189,994,852Oligonucleotide compositions and uses thereofPharmaceuticalsMIRAGEN THERAPEUTICS, INC.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 18, 20252025/0382374COMPOSITIONS AND METHODS FOR TREATMENT OF THYROID EYE DISEASEPharmaceuticalsViridian Therapeutics, Inc.
Oct 9, 20252025/0313639COMPOSITIONS AND METHODS FOR TREATMENT OF THYROID EYE DISEASEPharmaceuticalsViridian Therapeutics, Inc.
May 15, 20252025/0152704FCRN ANTAGONISTS WITH IMPROVED HALF-LIFE AND METHODS OF USEBiotechnologyViridian Therapeutics, Inc.
Mar 27, 20252025/0099583PHARMACEUTICAL COMPOSITIONS OF ANTI-IGF-1R ANTIBODIESPharmaceuticalsViridian Therapeutics, Inc.
Feb 20, 20252025/0059287COMPOSITIONS AND METHODS FOR TREATMENT OF THYROID EYE DISEASEPharmaceuticalsViridian Therapeutics, Inc.
Oct 31, 20242024/0360227COMPOSITIONS AND METHODS FOR TREATMENT OF THYROID EYE DISEASEPharmaceuticalsViridian Therapeutics, Inc.
Oct 24, 20242024/0352133COMPOSITIONS AND METHODS FOR TREATMENT OF THYROID EYE DISEASEPharmaceuticalsViridian Therapeutics, Inc.
Oct 17, 20242024/0343814COMPOSITIONS AND METHODS FOR TREATMENT OF THYROID EYE DISEASEPharmaceuticalsViridian Therapeutics, Inc.
Oct 17, 20242024/0343812COMPOSITIONS, DOSES, AND METHODS FOR TREATMENT OF THYROID EYE DISEASEPharmaceuticalsViridian Therapeutics, Inc. · patent 12,404,337 granted from it
Feb 8, 20242024/0043546COMPOSITIONS AND METHODS FOR TREATMENT OF THYROID EYE DISEASEPharmaceuticalsViridian Therapeutics, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 9 · Biotechnology 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton VRDN · research, not advice